Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …

Background Older patients with acute myeloid leukemia (AML) have a dismal prognosis,
even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …

Effective treatment options are limited for patients with acute myeloid leukemia (AML) who
cannot tolerate intensive chemotherapy. Adults age≥ 18 years with newly diagnosed AML …

PURPOSE Sixty percent of newly diagnosed patients with acute myeloid leukemia (ND-
AML) receiving frontline therapy attain a complete response (CR), yet 30%-40% of patients …

Fat mass and obesity-associated protein (FTO), an RNA N 6-methyladenosine (m 6 A)
demethylase, plays oncogenic roles in various cancers, presenting an opportunity for the …

With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …

The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …